Novel Biomarkers of Alzheimer’s Disease: Based Upon N-methyl-D-aspartate Receptor Hypoactivation and Oxidative Stress

키워드

참고문헌 (124)

1. Scheltens P, "Alzheimer’s disease", Lancet, 388, pp.505~517 (2016)
2. Lyketsos CG, "Neuropsychiatric symptoms in Alzheimer’s disease", Alzheimers Dement, 7, pp.532~539 (2011)
3. Marešová P, "Socio-economic aspects of Alzheimer’s disease", Curr Alzheimer Res, 12, pp.903~911 (2015)
4. Alzheimer’s Association, "2016 Alzheimer’s disease facts and figures", Alzheimers Dement, 12, pp.459~509 (2016)
5. LiverTox: clinical and research information on drug-induced liver injury, "National Institute of Diabetes and Digestive and Kidney Diseases", National Institute of Diabetes and Digestive and Kidney Diseases, ~ (2012)
6. Maki Y, "Early detection of dementia in the community under a community-based integrated care system", Geriatr Gerontol Int, 14(Suppl 2), pp.2~10 (2014)
7. Crous-Bou M, "Alzheimer’s disease prevention : from risk factors to early intervention", Alzheimers Res Ther, 9, pp.71~ (2017)
8. Karch CM, "Alzheimer’s disease risk genes and mechanisms of disease pathogenesis", Biol Psychiatry, 77, pp.43~51 (2015)
9. Barage SH, "Amyloid cascade hypothesis : pathogenesis and therapeutic strategies in Alzheimer’s disease", Neuropeptides, 52, pp.1~18 (2015)
10. Jellinger KA, "Basic mechanisms of neurodegeneration : a critical update", J Cell Mol Med, 14, pp.457~487 (2010)
11. Rao VK, "Mitochondrial permeability transition pore is a potential drug target for neurodegeneration", Biochim Biophys Acta, 1842, pp.1267~1272 (2014)
12. Ramirez Diaz SP, "Enfermedad de Alzheimer. Presente y futuro" (2011), PyDESA
13. "The etiology of Alzheimer’s disease" (2016)[URL]
14. Domínguez RO, "Alzheimer disease and cognitive impairment associated with diabetes mellitus type 2 : associations and a hypothesis", Neurologia, 29, pp.567~572 (2014)
15. Sandhir R, "Molecular and biochemical trajectories from diabetes to Alzheimer’s disease : a critical appraisal", World J Diabetes, 6, pp.1223~1242 (2015)
16. Jayaraj RL, "Diabetes as a risk factor for Alzheimer’s disease in the Middle East and its shared pathological mediators", Saudi J Biol Sci, 27, pp.736~750 (2020)
17. Nakabeppu Y, "Molecular pathophysiology of insulin depletion, mitochondrial dysfunction, and oxidative stress in Alzheimer’s disease brain", Adv Exp Med Biol, 1128, pp.27~44 (2019)
18. Shaw LM, "Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects", Ann Neurol, 65, pp.403~413 (2009)
19. Visser PJ, "Prevalence and prognostic value of CSF markers of Alzheimer’s disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study : a prospective cohort study", Lancet Neurol, 8, pp.619~627 (2009)
20. Blennow K, "Biomarkers for Alzheimer’s disease : current status and prospects for the future", J Intern Med, 284, pp.643~663 (2018)
21. Hansson O, "Prediction of Alzheimer’s disease using the CSF Abeta42", Abeta40 ratio in patients with mild cognitive impairment, 2007, pp.23, 316~320
22. Wiltfang J, "Amyloid beta peptide ratio 42", 40 but not A beta 42correlates with phospho-Tau in patients with low-and high-CSF A beta 40 load, 2007, pp.101, 1053~1059
23. Blennow K, "CSF markers for incipient Alzheimer’s disease", Lancet Neurol, 2, pp.605~613 (2003)
24. Riemenschneider M, "Phospho-tau", total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias, 2003, pp.8, 343~347
25. Wallin AK, "CSF biomarkers predict a more malignant outcome in Alzheimer disease", Neurology, 74, pp.1531~1537 (2010)
26. Hampel H, "Blood-based biomarkers for Alzheimer disease : mapping the road to the clinic", Nat Rev Neurol, 14, pp.639~652 (2018)
27. Khan TK, "Peripheral biomarkers of Alzheimer’s disease", J Alzheimers Dis, 44, pp.729~744 (2015)
28. Henriksen K, "The future of blood-based biomarkers for Alzheimer’s disease", Alzheimers Dement, 10, pp.115~131 (2014)
29. O’Bryant SE, "Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer’s disease research", Alzheimers Dement, 11, pp.549~560 (2015)
30. Zhao X, "A candidate plasma protein classifier to identify Alzheimer’s disease", J Alzheimers Dis, 43, pp.549~563 (2015)
31. Olsson B, "CSF and blood biomarkers for the diagnosis of Alzheimer’s disease : a systematic review and metaanalysis", Lancet Neurol, 15, pp.673~684 (2016)
32. Mitsushima D, "A cholinergic trigger drives learning-induced plasticity at hippocampal synapses", Nat Commun, 4, pp.2760~ (2013)
33. Kaduszkiewicz H, "Cholinesterase inhibitors for patients with Alzheimer’s disease : systematic review of randomised clinical trials", BMJ, 331, pp.321~327 (2005)
34. Raina P, "Effectiveness of cholinesterase inhibitors and memantine for treating dementia : evidence review for a clinical practice guideline", Ann Intern Med, 148, pp.379~397 (2008)
35. O’Brien JT, "Clinical practice with anti-dementia drugs : a revised(second)consensus statement from the British Association for Psychopharmacology", J Psychopharmacol, 25, pp.997~1019 (2011)
36. Blanco-Silvente L, "Discontinuation, efficacy, and safety of cholinesterase inhibitors for Alzheimer’s disease : a meta-analysis and meta-regression of 43 randomized clinical trials enrolling 16 106 patients", Int J Neuropsychopharmacol, 20, pp.519~528 (2017)
37. McShane R, "Memantine for dementia", Cochrane Database Syst Rev, 3, pp.CD003154~ (2019)
38. O’Brien JT, "Clinical practice with anti-dementia drugs : a revised(third)consensus statement from the British Association for Psychopharmacology", J Psychopharmacol, 31, pp.147~168 (2017)
39. Vandenberghe R, "Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials", Alzheimers Res Ther, 8, pp.18~ (2016)
40. Honig LS, "Trial of solanezumab for mild dementia due to Alzheimer’s disease", N Engl J Med, 378, pp.321~330 (2018)
41. Kennedy ME, "The BACE1 inhibitor verubecestat(MK-8931)reduces CNS -amyloid in animal models and in Alzheimer’s disease patients", Sci Transl Med, 8, pp.363~ (2016)
42. Egan MF, "Randomized trial of verubecestat for mild-to-moderate Alzheimer’s disease", N Engl J Med, 378, pp.1691~1703 (2018)
43. Egan MF, "Randomized trial of verubecestat for prodromal Alzheimer’s disease", N Engl J Med, 380, pp.1408~1420 (2019)
44. Cummings JL, "ABBY : A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease", Neurology, 90, pp.e1889~ (2018)
45. "Genentech’s crenezumab fails two phase III trials in Alzheimer’s 2019" (2019)[URL]
46. "Trials of promising Alzheimer drug stopped" (2019)[URL]
47. "Ongoing Alzheimers and related clinical trials and studies" (2019)[URL]
48. Selkoe DJ, "Alzheimer disease and aducanumab : adjusting our approach", Nat Rev Neurol, 15, pp.365~366 (2019)
49. Hsu WY, "Effects of noninvasive brain stimulation on cognitive function in healthy aging and Alzheimer’s disease : a systematic review and meta-analysis", Neurobiol Aging, 36, pp.2348~2359 (2015)
50. Aldehri M, "Deep brain stimulation for Alzheimer’s Disease : an update", Surg Neurol Int, 9, pp.58~ (2018)
51. Chang CH, "Brain stimulation in Alzheimer’s disease", Front Psychiatry, 9, pp.201~ (2018)
52. Garcia-Casares N, "Music therapy as a non-pharmacological treatment in Alzheimer’s disease. A systematic review", Rev Neurol, 65, pp.529~538 (2017)
53. Maliszewska-Cyna E, "The benefits of exercise and metabolic interventions for the prevention and early treatment of Alzheimer’s disease", Curr Alzheimer Res, 14, pp.47~60 (2017)
54. Karran E, "The amyloid cascade hypothesis for Alzheimer’s disease : an appraisal for the development of therapeutics", Nat Rev Drug Discov, 10, pp.698~712 (2011)
55. Boyle PA, "Much of late life cognitive decline is not due to common neurodegenerative pathologies", Ann Neurol, 74, pp.478~489 (2013)
56. Mendiola-Precoma J, "Therapies for prevention and treatment of Alzheimer’s disease", Biomed Res Int, 2016, pp.2589276~ (2016)
57. Mattson MP, "Glutamate and neurotrophic factors in neuronal plasticity and disease", Ann N Y Acad Sci, 1144, pp.97~112 (2008)
58. Hashimoto K, "Abnormality in glutamine-glutamate cycle in the cerebrospinal fluid of cognitively intact elderly individuals with major depressive disorder : a 3-year follow-up study", Transl Psychiatry, 6, pp.e744~ (2016)
59. Chan YE, "Treatment-resistant depression enhances risks of dementia and Alzheimer’s disease : a nationwide longitudinal study", J Affect Disord, 274, pp.806~812 (2020)
60. Husi H, "NMDA receptors, neural pathways, and protein interaction databases", Int Rev Neurobiol, 61, pp.49~77 (2004)
61. Zito K, "Encyclopedia of neuroscience", pp.1157~1164 (2009), Academic Press
62. Miller SL, "Conn’s translational neuroscience", pp.49~84 (2017), Academic Press
63. Albensi BC, "The NMDA receptor", ion channel complex : a drug target for modulating synaptic plasticity and excitotoxicity, 2007, pp.13, 3185~3194
64. Newcomer JW, "NMDA receptor function, memory, and brain aging", Dialogues Clin Neurosci, 2, pp.219~232 (2000)
65. Findley CA, "Amyloid beta-related alterations to glutamate signaling dynamics during Alzheimer’s disease progression", ASN Neuro, 11, pp.1759091419855541~ (2019)
66. Aizenstein HJ, "Where is hippocampal activity in the cascade of Alzheimer’s disease biomarkers?", Brain, 138(Pt 4), pp.831~833 (2015)
67. Huijbers W, "Amyloid-β deposition in mild cognitive impairment is associated with increased hippocampal activity, atrophy and clinical progression", Brain, 138(Pt 4), pp.1023~1035 (2015)
68. Ulas J, "Decreased expression of N-methyl-Daspartate receptor 1 messenger RNA in select regions of Alzheimer brain", Neuroscience, 79, pp.973~982 (1997)
69. Zhang J, "The role of N-methyl-D-aspartate receptor in Alzheimer’s disease", J Neurol Sci, 339, pp.123~129 (2014)
70. Sohal RS, "Oxidative stress as a causal factor in differentiation and aging : a unifying hypothesis", Exp Gerontol, 25, pp.499~522 (1990)
71. García-Blanco A, "Potential oxidative stress biomarkers of mild cognitive impairment due to Alzheimer disease", J Neurol Sci, 373, pp.295~302 (2017)
72. Pohanka M, "Oxidative stress in Alzheimer disease as a target for therapy", Bratisl Lek Listy, 119, pp.535~543 (2018)
73. Swerdlow RH, "The Alzheimer’s disease mitochondrial cascade hypothesis : progress and perspectives", Biochim Biophys Acta, 1842, pp.1219~1231 (2014)
74. Beal MF, "Mitochondria take center stage in aging and neurodegeneration", Ann Neurol, 58, pp.495~505 (2005)
75. Du H, "Early deficits in synaptic mitochondria in an Alzheimer’s disease mouse model", Proc Natl Acad Sci U S A, 107, pp.18670~18675 (2010)
76. Bubber P, "Mitochondrial abnormalities in Alzheimer brain : mechanistic implications", Ann Neurol, 57, pp.695~703 (2005)
77. Reddy PH, "Abnormal tau, mitochondrial dysfunction, impaired axonal transport of mitochondria, and synaptic deprivation in Alzheimer’s disease", Brain Res, 1415, pp.136~148 (2011)
78. Caldwell CC, "Targeting the prodromal stage of Alzheimer’s disease : bioenergetic and mitochondrial opportunities", Neurotherapeutics, 12, pp.66~80 (2015)
79. Uttara B, "Oxidative stress and neurodegenerative diseases : a review of upstream and downstream antioxidant therapeutic options", Curr Neuropharmacol, 7, pp.65~74 (2009)
80. Chen Z, "Oxidative stress in Alzheimer’s disease", Neurosci Bull, 30, pp.271~281 (2014)
81. Lovell MA, "Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer’s disease", Neurology, 45, pp.1594~1601 (1995)
82. Butterfield DA, "Elevated protein-bound levels of the lipid peroxidation product, 4-hydroxy-2-nonenal, in brain from persons with mild cognitive impairment", Neurosci Lett, 397, pp.170~173 (2006)
83. Keller JN, "Evidence of increased oxidative damage in subjects with mild cognitive impairment", Neurology, 64, pp.1152~1156 (2005)
84. Poprac P, "Targeting free radicals in oxidative stress-related human diseases", Trends Pharmacol Sci, 38, pp.592~607 (2017)
85. Gwon AR, "Oxidative lipid modification of nicastrin enhances amyloidogenic -secretase activity in Alzheimer’s disease", Aging Cell, 11, pp.559~568 (2012)
86. Greenough MA, "Metal dyshomeostasis and oxidative stress in Alzheimer’s disease", Neurochem Int, 62, pp.540~555 (2013)
87. Wang P, "Metal ions influx is a double edged sword for the pathogenesis of Alzheimer’s disease", Ageing Res Rev, 35, pp.265~290 (2017)
88. Deibel MA, "Copper, iron, and zinc imbalances in severely degenerated brain regions in Alzheimer’s disease : possible relation to oxidative stress", J Neurol Sci, 143, pp.137~142 (1996)
89. Lovell MA, "Copper, iron and zinc in Alzheimer’s disease senile plaques", J Neurol Sci, 158, pp.47~52 (1998)
90. Friedlich AL, "Neuronal zinc exchange with the blood vessel wall promotes cerebral amyloid angiopathy in an animal model of Alzheimer’s disease", J Neurosci, 24, pp.3453~3459 (2004)
91. Lee JY, "Histochemically reactive zinc in plaques of the Swedish mutant beta-amyloid precursor protein transgenic mice", J Neurosci, 19, pp.RC10~ (1999)
92. Suh SW, "Histochemically-reactive zinc in amyloid plaques, angiopathy, and degenerating neurons of Alzheimer’s diseased brains", Brain Res, 852, pp.274~278 (2000)
93. Choi Y, "Three pairs of cysteine residues mediate both redox and Zn2＋ modulation of the nmda receptor", J Neurosci, 21, pp.392~400 (2001)
94. Hardingham GE, "Synaptic versus extrasynaptic NMDA receptor signalling : implications for neurodegenerative disorders", Nat Rev Neurosci, 11, pp.682~696 (2010)
95. Choi YB, "Identification and mechanism of action of two histidine residues underlying high-affinity Zn2＋ inhibition of the NMDA receptor", Neuron, 23, pp.171~180 (1999)
96. Köhr G, "NMDA receptor channels : subunit-specific potentiation by reducing agents", Neuron, 12, pp.1031~1040 (1994)
97. Steullet P, "Synaptic plasticity impairment and hypofunction of NMDA receptors induced by glutathione deficit : relevance to schizophrenia", Neuroscience, 137, pp.807~819 (2006)
98. Radonjic NV, "Decreased glutathione levels and altered antioxidant defense in an animal model of schizophrenia : long-term effects of perinatal phencyclidine administration", Neuropharmacology, 58, pp.739~745 (2010)
99. Papadia S, "Synaptic NMDA receptor activity boosts intrinsic antioxidant defenses", Nat Neurosci, 11, pp.476~487 (2008)
100. Jiang Z, "Social isolation exacerbates schizophrenia-like phenotypes via oxidative stress in cortical interneurons", Biol Psychiatry, 73, pp.1024~1034 (2013)
101. Mauceri D, "Dual role of CaMKII-dependent SAP97 phosphorylation in mediating trafficking and insertion of NMDA receptor subunit NR2A", J Neurochem, 100, pp.1032~1046 (2007)
102. Bodhinathan K, "Intracellular redox state alters NMDA receptor response during aging through Ca2＋", calmodulin-dependent protein kinase II, 2010, pp.30, 1914~1924
103. Reese LC, "Dysregulated phosphorylation of Ca2＋", calmodulin-dependent protein kinase II- in the hippocampus of subjects with mild cognitive impairment and Alzheimer’s disease, 2011, pp.119, 791~804
104. Steullet P, "Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: a “central hub” in schizophrenia pathophysiology?", Schizophr Res, 176, pp.41~51 (2016)
105. Belforte JE, "Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes", Nat Neurosci, 13, pp.76~83 (2010)
106. Powell SB, "Behavioral and neurochemical consequences of cortical oxidative stress on parvalbumin-interneuron maturation in rodent models of schizophrenia", Neuropharmacology, 62, pp.1322~1331 (2012)
107. Wang X, "How Nox2-containing NADPH oxidase affects cortical circuits in the NMDA receptor antagonist model of schizophrenia", Antioxid Redox Signal, 18, pp.1444~1462 (2013)
108. Hardingham GE, "Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis", Nat Rev Neurosci, 17, pp.125~134 (2016)
109. Goussakov I, "NMDA-mediated Ca2＋ influx drives aberrant ryanodine receptor activation in dendrites of young Alzheimer’s disease mice", J Neurosci, 30, pp.12128~12137 (2010)
110. Lane HY, "Add-on treatment of benzoate for schizophrenia : a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor", JAMA Psychiatry, 70, pp.1267~1275 (2013)
111. Tsai GE, "Improved cognition in Alzheimer’s disease with short-term D-cycloserine treatment", Am J Psychiatry, 156, pp.467~469 (1999)
112. Schwartz BL, "d-Cycloserine enhances implicit memory in Alzheimer patients", Neurology, 46, pp.420~424 (1996)
113. Randolph C, "D-cycloserine treatment of Alzheimer disease", Alzheimer Dis Assoc Disord, 8, pp.198~205 (1994)
114. Tsai GE, "A preliminary study of D-cycloserine treatment in Alzheimer’s disease", J Neuropsychiatry Clin Neurosci, 10, pp.224~226 (1998)
115. Chang CH, "Effect of N-methyl-D-aspartate-receptor-enhancing agents on cognition in patients with schizophrenia : a systematic review and meta-analysis of double-blind randomised controlled trials", J Psychopharmacol, 33, pp.436~448 (2019)
116. Yao L, "Enhancing NMDA receptor function : recent progress on allosteric modulators", Neural Plast, 2017, pp.2875904~ (2017)
117. Hashimoto K, "Possible role of D-serine in the pathophysiology of Alzheimer’s disease", Prog Neuropsychopharmacol Biol Psychiatry, 28, pp.385~388 (2004)
118. Biemans EA, "CSF D-serine concentrations are similar in Alzheimer’s disease, other dementias, and elderly controls", Neurobiol Aging, 42, pp.213~216 (2016)
119. Madeira C, "D-serine levels in Alzheimer’s disease : implications for novel biomarker development", Transl Psychiatry, 5, pp.e561~ (2015)
120. Nuzzo T, "Cerebrospinal fluid and serum d-serine concentrations are unaltered across the whole clinical spectrum of Alzheimer’s disease", Biochim Biophys Acta Proteins Proteom, 1868, pp.140537~ (2020)
121. Lin CH, "Glutamate signaling in the pathophysiology and therapy of schizophrenia", Pharmacol Biochem Behav, 100, pp.665~677 (2012)
122. Lin CH, "Early identification and intervention of schizophrenia : insight from hypotheses of glutamate dysfunction and oxidative stress", Front Psychiatry, 10, pp.93~ (2019)
123. Van den Berghe-Snorek S, "Thermodynamic control of D-amino acid oxidase by benzoate binding", J Biol Chem, 260, pp.3373~3379 (1985)
124. Lin CH, "Benzoate, a D-amino acid oxidase inhibitor, for the treatment of early-phase Alzheimer disease : a randomized, double-blind, placebo-controlled trial", Biol Psychiatry, 75, pp.678~685 (2014)

관련 논문AI추천